{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:55:45Z","timestamp":1770274545657,"version":"3.49.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2010,11,22]],"date-time":"2010-11-22T00:00:00Z","timestamp":1290384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrotic changes in skin and other organs involving excessive collagen deposition. Here we investigated the effect of intravenous immunoglobulin (IVIG) on fibrosis in a murine model of bleomycin (BLM)-induced scleroderma. Scleroderma was induced in C3H\/He J mice by subcutaneous BLM injections daily for 35 days. The collagen content in skin samples from the BLM-injected group (6\u00b730\u2003\u00b1\u20030\u00b711\u2003mg\/g tissue) was significantly higher than the PBS group (5\u00b780\u2003\u00b1\u20030\u00b710\u2003mg\/g tissue), and corresponded with dermal thickening at the injection site. In contrast, mice treated with IVIG for 5 consecutive days after initiating BLM injection showed lesser collagen content significantly (IVIG group, 5\u00b761\u2003\u00b1\u20030\u00b709\u2003mg\/g tissue; BLM vs. IVIG). In order to investigate the cellular and protein characteristics in the early stage of the model, the skin samples were obtained 7 days after the onset of experiment. Macrophage infiltration to the dermis, monocyte chemoattractant protein (MCP-1)-positive cells, and increased TGF-\u03b21 mRNA expression were also observed in the BLM group. IVIG inhibited these early fibrogenic changes; MCP-1 expression was significantly lesser for the IVIG group (1\u00b752\u2003\u00b1\u20030\u00b719\u2003pg\/mg tissue) than for the BLM group (2\u00b749\u2003\u00b1\u20030\u00b726\u2003pg\/mg tissue). In contrast, TGF-\u03b21 mRNA expression was significantly inhibited by IVIG. These results suggest that IVIG treatment may inhibit macrophage recruitment to fibrotic sites by down regulating MCP-1 and TGF-\u03b2 production, and thus could be a potential drug for managing fibrotic disorders such as SSc.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2010.04295.x","type":"journal-article","created":{"date-parts":[[2010,11,22]],"date-time":"2010-11-22T16:52:28Z","timestamp":1290444748000},"page":"235-241","source":"Crossref","is-referenced-by-count":28,"title":["Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma"],"prefix":"10.1093","volume":"163","author":[{"given":"M","family":"Kajii","sequence":"first","affiliation":[{"name":"Osaka Research Laboratory, Benesis Corporation, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Osaka Research Laboratory, Benesis Corporation, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Kashihara","sequence":"additional","affiliation":[{"name":"Osaka Research Laboratory, Benesis Corporation, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Osaka Research Laboratory, Benesis Corporation, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Kubo","sequence":"additional","affiliation":[{"name":"Osaka Research Laboratory, Benesis Corporation, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Osaka Research Laboratory, Benesis Corporation, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Yuuki","sequence":"additional","affiliation":[{"name":"Osaka Research Laboratory, Benesis Corporation, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Fukushima Medical University, Fukushima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Nakae","sequence":"additional","affiliation":[{"name":"Osaka Research Laboratory, Benesis Corporation, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,11,22]]},"reference":[{"key":"2021122708482400100_b1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.autrev.2006.03.010","article-title":"Common variable immune deficiency and autoimmunity","volume":"5","author":"Brandt","year":"2006","journal-title":"Autoimmun Rev"},{"key":"2021122708482400100_b2","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1365-2133.2007.07777.x","article-title":"High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma","volume":"156","author":"Ihn","year":"2007","journal-title":"Br J Dermatol"},{"key":"2021122708482400100_b3","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/art.20195","article-title":"Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study","volume":"50","author":"Levy","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2021122708482400100_b4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1046\/j.1365-2249.2001.01499.x","article-title":"Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition","volume":"124","author":"Wada","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"2021122708482400100_b5","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/art.22521","article-title":"A new murine model to define the critical pathologic and therapeutic mediators of polymyositis","volume":"56","author":"Sugihara","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2021122708482400100_b6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0306-3623(98)00004-4","article-title":"Involvement of CD4+ T cells in the development of dextran sulfate sodium-induced experimental colitis and suppressive effect of IgG on their action","volume":"31","author":"Shintani","year":"1998","journal-title":"Gen Pharmacol"},{"key":"2021122708482400100_b7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.autrev.2008.04.011","article-title":"Role of natural antibodies in immune homeostasis: IVIG perspective","volume":"7","author":"Vani","year":"2008","journal-title":"Autoimmun Rev"},{"key":"2021122708482400100_b8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1006\/clim.1999.4720","article-title":"Anti-sclerotic effect of transforming growth factor-\u03b2 antibody in a mouse model of bleomycin-induced scleroderma","volume":"92","author":"Yamamoto","year":"1999","journal-title":"Clin Immunol"},{"key":"2021122708482400100_b9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2249.2005.02718.x","article-title":"Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma","volume":"139","author":"Matsushita","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"2021122708482400100_b10","first-page":"377","article-title":"Animal models of scleroderma","volume":"102","author":"Lakos","year":"2004","journal-title":"Method Mol Med"},{"key":"2021122708482400100_b11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s004030000183","article-title":"Animal model of sclerotic skin. III: histopathological comparison of bleomycin-induced scleroderma in various mice strains","volume":"292","author":"Yamamoto","year":"2000","journal-title":"Arch Dermatol Res"},{"key":"2021122708482400100_b12","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat Protoc"},{"key":"2021122708482400100_b13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00403-005-0635-z","article-title":"The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?","volume":"297","author":"Yamamoto","year":"2006","journal-title":"Arch Dermatol Res"},{"key":"2021122708482400100_b14","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(06)68737-0","article-title":"Systemic sclerosis: hypothesis-driven treatment strategies","volume":"367","author":"Charles","year":"2006","journal-title":"The Lancet"},{"key":"2021122708482400100_b15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000094242","article-title":"Chemokines and chemokine receptors in scleroderma","volume":"140","author":"Yamamoto","year":"2006","journal-title":"Int Arch Allergy Immunol"},{"key":"2021122708482400100_b16","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1046\/j.1523-1747.2003.12408.x","article-title":"Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma","volume":"121","author":"Yamamoto","year":"2003","journal-title":"Invest Dermatol"},{"key":"2021122708482400100_b17","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.4049\/jimmunol.164.12.6174","article-title":"Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop","volume":"164","author":"Yamamoto","year":"2000","journal-title":"J Immunol"},{"key":"2021122708482400100_b18","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/sj.jid.5700302","article-title":"Diminished induction of skin fibrosis in mice with MCP-1 deficiency","volume":"126","author":"Ferreira","year":"2006","journal-title":"J Invest Dermatol"},{"key":"2021122708482400100_b19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jcp.21750","article-title":"Role of Connective tissue growth factor and its interaction with basic fibroblast growth factor and macrophage chemoattractant protein-1 in skin fibrosis","volume":"220","author":"Chujo","year":"2009","journal-title":"J Cell Physiol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2010.04295.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/163\/2\/235\/41909834\/j.1365-2249.2010.04295.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/163\/2\/235\/41909834\/j.1365-2249.2010.04295.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:18:09Z","timestamp":1641053889000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/163\/2\/235\/6428864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,22]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2010,11,22]]},"published-print":{"date-parts":[[2011,1,5]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04295.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,2]]},"published":{"date-parts":[[2010,11,22]]}}}